Gonadorelin
GnRH Agonist (endogenous sequence)Also known as: GnRH · LHRH · Luteinizing Hormone-Releasing Hormone
The native 10-amino-acid gonadotropin-releasing hormone. Stimulates LH & FSH release from the pituitary. Used in fertility treatment & TRT to maintain testicular function.
Typical Dose
100 mcg 2x/week (TRT preservation); 50–100 mcg multiple times daily for fertility induction
Route
Subcutaneous injection
Cycle
Continuous alongside TRT; or 4–8 weeks for fertility
Half-life
~2–4 minutes (very short; use pulsatile dosing only)
Storage
Reconstituted: 2–8°C, use within 30 days.
Overview
Gonadorelin is the endogenous 10-amino-acid decapeptide produced by the hypothalamus that triggers pulsatile release of LH & FSH from the anterior pituitary. The pulsatile nature of its release is essential — continuous GnRH exposure paradoxically suppresses LH & FSH via receptor desensitization (the mechanism exploited by long-acting GnRH agonists in oncology).
In the context of male testosterone replacement therapy (TRT), gonadorelin is administered in a pulsatile fashion (2x/week) to preserve Leydig cell function & testicular volume, maintain sperm production, & prevent the HPG axis shutdown associated with exogenous testosterone alone.
In fertility medicine, pulsatile gonadorelin delivery via pump is used for hypothalamic amenorrhea & hypogonadotropic hypogonadism.
Quick Start Guide
TRT preservation protocol: inject 100 mcg SubQ twice weekly (not daily — maintain pulsatile pattern).
Reconstitute with 2 mL BAC water per 2 mg vial.
Research Indications
HPG axis preservation during TRT
EffectiveMaintains LH/FSH signaling to testes during exogenous testosterone use. Preserves testicular volume & sperm production.
Hypogonadotropic hypogonadism / fertility
Most EffectivePulsatile GnRH therapy is the treatment of choice for hypothalamic amenorrhea & hypothalamic male hypogonadism.
Research Protocols
TRT fertility/testicular preservation
Continuous alongside TRTDose
100 mcg
Frequency
Twice weekly SubQ
Route
SubQ abdomen
Hypogonadism / fertility induction
4–8 weeks per cycleDose
5–20 mcg per pulse via pump
Frequency
Every 60–120 minutes (pulsatile pump)
Route
SubQ or IV pump
Side Effects & Safety
Common
- Injection site redness
- Headache
- Nausea (at higher doses)
Uncommon
- Hypersensitivity reactions
- Ovarian hyperstimulation syndrome (OHSS) in women
When to Stop
- Signs of OHSS
- Signs of allergic reaction
How to Reconstitute
Wipe stopper. Add 2 mL BAC water. Swirl gently. Refrigerate.
Dosing math: 2 mL BAC water per 2 mg = 1000 mcg/mL. For 100 mcg: 0.1 mL.
Quality Indicators
Good — use as normal
- Clear, colorless solution
Acceptable
- Very faint tint
Discard immediately
- Cloudiness
- Particulate
What to Expect
Week 1–4
LH & FSH begin to rise with twice-weekly injection. Testicular function maintained alongside TRT.
Month 2–3
Testicular volume preservation confirmed. Sperm count maintained in most men.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Research References
Pulsatile gonadotropin-releasing hormone therapy for men with hypogonadotropic hypogonadism
Journal of Urology · 1994
Demonstrates fertility restoration in hypogonadotropic hypogonadism with pulsatile GnRH pump therapy.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample